Application of Tempol in preparation of medicine for treating polycystic ovarian syndrome

A polycystic ovary syndrome technology, which is applied in the application field of preparing a drug for the treatment of polycystic ovary syndrome, and achieves the effects of improving PCOS, having broad application prospects, and relieving abundance and

Active Publication Date: 2021-03-02
BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1 oxygen radical) is an azacyclohexane nitroxide with strong stability, high cell membrane permeability a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Tempol in preparation of medicine for treating polycystic ovarian syndrome
  • Application of Tempol in preparation of medicine for treating polycystic ovarian syndrome
  • Application of Tempol in preparation of medicine for treating polycystic ovarian syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] The construction of embodiment 1 animal model

[0075] Three-week-old SD rats were divided into three groups: control group (Oil+PBS group), PCOS model group (DHEA+PBS group), Tempol treatment group (DHEA+Tempol group). There were 6-11 rats in each group, and the construction method of the rat model in the control group was as follows: 200 μL of sesame oil was injected subcutaneously, and after 21 days of continuous injection, PBS was injected intraperitoneally for 12 consecutive days; Hydroepiandrosterone (DHEA) (Solarbio, D8950) 6mg / 100g, 200 μ L, after continuous injection for 21 days, intraperitoneal injection of PBS for 12 consecutive days; the construction method of the Tempol treatment group rat model is as follows: subcutaneous injection of DHEA ) 6mg / 100g, 200μL, after continuous injection for 21 days, Tempol (30mg / kg) (Selleck Chemicals LLC#S2910, Houston, TX, USA) was injected intraperitoneally for 12 consecutive days. Weighing was performed weekly during th...

Embodiment 2

[0077] Example 2 The observation of rat estrous cycle, the observation of ovarian histomorphology and the measurement and analysis of serum hormones 1, the observation of rat estrous cycle

[0078] Rats are animals with multiple estrus throughout the year and have a relatively stable sexual cycle, which is divided into: preestrus (P), estrus (E), postestrus (M) and diestrus (D). The vaginal mucosa of each period is Typical changes occur, which stage can be judged according to the cytological characteristics of the vaginal smear. In this embodiment, 3 rats in the control group (Oil+PBS group), PCOS model group (DHEA+PBS group), and Tempol treatment group (DHEA+Tempol group) three groups of experimental animals were taken from the vagina at the same time every afternoon. The cell smears were stained with Wright's staining solution (LEAGENE, 1029A20) for 10 consecutive days to observe the cell morphology and record and count the experimental results respectively.

[0079] 2. HE ...

Embodiment 3

[0086] Example 3 Statistical analysis on biomarker level

[0087] 1. 16S rRNA gene sequencing

[0088] Total bacterial DNA was extracted from feces using a DNA isolation kit (MO BIO Laboratories, Carlsbad, CA, USA). The quality and quantity of DNA were evaluated by the ratio of 260nm / 280nm and 260nm / 230nm. DNA was then stored at -80°C until further processing. The V3-V4 region of the bacterial 16S rRNA gene was amplified with common primers (SEQ ID NO.1-SEQ ID NO.2) in combination with the adapter sequence and the barcode sequence. Thermal cycling conditions were: initial denaturation at 95°C for 5 min, followed by 15 cycles of denaturation at 95°C for 1 min, 50°C for 1 min and 72°C for 1 min, and finally extension at 72°C for 7 min. The first step PCR product is purified by VAHTSTM DNA cleaning beads. The second round of PCR was performed in a 40 μL reaction consisting of 20 μL 2× Phμsion HF-MM, 8 μL ddH 2 O. 10 μM of each primer and 10 μL of the PCR product from the fir...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of Tempol in preparation of a medicine for treating polycystic ovarian syndrome, animal experiments discover that Tempol can reduce the androgen level of mammals, recover the ovulation function of mammals, improve the polycystic change of ovaries, relieve the change of intestinal flora and relieve the difference change of serum metabolites for the first time,then PCOS can be obviously improved and a significant curative effect is obtained. The invention provides a new technical means for the treatment of PCOS, has very important significance for the clinical treatment and/or adjuvant therapy of PCOS, and has wide application prospects.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of Tempol in the preparation of medicines for treating polycystic ovary syndrome. Background technique [0002] Polycystic ovary syndrome (PCOS) is an endocrine disorder and metabolic abnormality with complex etiology and various clinical manifestations. Hormone production excess), the main clinical manifestations are irregular menstrual cycle, infertility, hirsutism and / or acne, which is widely considered to be a combination of ovulatory dysfunction, excess androgen levels and ovarian polycystic changes, excluding the possibility of causing similar Depression, lack of self-confidence and other mood disorders often occur. Its etiology and specific pathogenesis have not yet been elucidated, and studies suggest that it may be related to certain genetic variations, environmental factors, and metabolic abnormalities. Currently, about 4% to 8% of women worldwid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/445A61K35/74A61K49/00A61P15/00A61P15/08A61D7/00
CPCA61K31/445A61K35/74A61K49/0008A61P15/00A61P15/08A61D7/00A61K2300/00
Inventor 李天鹤阴赪宏刘瑞霞张婷婷
Owner BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap